Medicilon Intermediate Synthesis Service

As a provider of global chemical services, Medicilon has a strong analytical chemistry team to support synthetic chemistry services. We are committed to providing customers with the highest quality and most valuable products and services through prolific, fast, problem-solving and active communication. Our team has received excellent professional training, keeps close contact and interaction with customers, communicates in time to ensure the smooth progress of the project, and makes concerted efforts to achieve the project goals specified by the customer. In FTE’s service model, we design a synthetic route for the customer’s target molecule, and complete the synthesis and delivery of the compound on time, quality and quantity. These compounds include reference compounds, metabolites, reagents, intermediates, molecular fragments and impurities.

Pharmaceutical Intermediate Synthesis

Medicilon synthesizes various small molecule chemical substances such as reference compounds, pharmaceutical intermediates, candidate drugs, impurities and metabolites for customers. The scale can range from milligrams to kilograms (including GMP quality). Our team is proficient in new route design and route optimization. With the proficient problem solving skills and the high success rate of the project, we are able to provide customers with the following high-quality chemical custom synthesis services:

Preparation of high-quality products from milligrams to kilograms
Synthesis of special reagents and pharmaceutical intermediates and preparation of molecular fragments
Preparation of APIs or related substances
Synthetic design and preparation of impurities and metabolites
Analysis support
Delivery of product analysis report

Click for service details

Medicilon’s chemical department is mainly engaged in the research and development and process optimization of high value-added new pharmaceutical intermediates, the research and development and process optimization of fine chemicals and the synthesis of raw materials, and is especially committed to natural products, special reagents, pharmaceutical intermediates, and pharmaceutical intermediates required for the research and development of new drugs. As well as the laboratory synthesis and amplification of various sugar compounds, the company has a factory base and advanced test equipment. The company has a comprehensive literature retrieval system, highly specialized chemical synthesis and process development capabilities, and high-level synthetic technical personnel.

Pharmaceutical intermediates, generally speaking, refer to those key raw materials specifically used to produce drugs, such as the key intermediates 6-APA (6-aminopenicillanic acid), 7-ACA (7-amino Cephalosporan acid), 7-ADCA (7-aminodeacetoxycephalosporan acid), various cephalosporin side chains, and piperazine and its derivatives used in the production of quinolones, excluding those used Basic chemical raw materials used in drug production, such as ethanol and acetic acid.

Medicines can be divided into anti-cardiovascular drugs, anti-tumor drugs, endocrine system regulating drugs, antibiotics, etc. according to their uses, and each class of drugs contains a variety of drugs with different structures, such as: antibiotics including lactams, macrocyclic Esters, quinolones, chloramphenicol, etc. Since pharmaceutical intermediates are mainly used in the production of various drugs, they have a wide variety of types.

From the perspective of production, the pharmaceutical industry can be divided into two major categories: raw material drug production and preparation processing; raw material drug production can be divided into natural drugs and chemical drugs according to source, and can be divided into natural extracted drugs, biosynthetic drugs and chemically synthesized drugs according to production methods.

Phone: 02158591500

This article is about the synthesis of pharmaceutical intermediates and pharmaceutical intermediates. For more details, please contact us.

What is preclinical testing?

In the process of preclinical testing of a compound or biological agent into a drug, the compound involved must go through the testing phase. First, we need to identify potential targets that can treat the disease. Then, a variety of compounds or preparations are screened out. Any compound that has shown potential as a drug for the treatment of this disease needs to be tested for toxicity before clinical testing to reduce the possibility of injury. preclinical testing What is the basis of preclinical testing? According to US Food and Drug Administration (FDA) regulations, a series of tests are required before a new drug is approved for use. In the first stage, basic research determines a hypothetical target for the treatment of a certain disease, and then screens small molecules or biological compounds to discover any substance with the potential to treat the disease. Then, a preclinical research phase followed, before which, as described above, the potential toxicity of the compou

阅读全文

Inventory of the three major in vitro pharmacokinetic research methods

The metabolic properties of a compound are an essential factor in whether or not it can be used as a drug in the clinical setting, so pharmacokinetic studies of newly synthesized compounds are required in drug development. In vitro incubation with liver microsomes, recombinant CYP450 enzyme lines, and in vitro incubation with hepatocytes are some of the more common in vitro drug metabolism methods. 1. In vitro incubation method with liver microsomes The metabolic stability and metabolic phenotypes of candidate compounds in different species of liver microsomes are good predictors of the metabolic properties of compounds in vivo. They are practical tools for evaluating candidate compounds in the pre-development phase of drug development. Liver microsomes include rat liver microsomes, human liver microsomes, canine liver microsomes, monkey liver microsomes, and mouse liver microsomes. In in vitro incubation of the liver, microsomes are the "gold standard" for in vitro d

阅读全文

Novel Parkinson’s Therapies Possible with New Mouse Model

Parkinson's disease (PD) is a neurodegenerative disorder that is marked by the accumulation of the protein, α-synuclein (αS), into clumps known as Lewy bodies, which diminish neural health. Now, researchers from Brigham and Women's Hospital (BWH) report the development of a mouse model to induce PD-like αS aggregation, leading to resting tremor and abnormal movement control. The mouse responds to L-DOPA, similarly to patients with PD. The team's study (“Abrogating Native α-Synuclein Tetramers in Mice Causes a L-DOPA-Responsive Motor Syndrome Closely Resembling Parkinson’s Disease”) on the use of this transgenic mouse model appears in Neuron . “α-Synuclein (αS) regulates vesicle exocytosis but forms insoluble deposits in PD. Developing disease-modifying therapies requires animal models that reproduce cardinal features of PD. We recently described a previously unrecognized physiological form of αS, α-helical tetramers, and showed that familial PD-causing missense mutati

阅读全文

Shanghai Medicilon Inc.

搜索此博客